$ELV

Penczek Ronald W sold $149K of ELV

Penczek Ronald W (CAO & Controller) sold 369 shares of Elevance Health, Inc. (ELV) at $403.16 ($0.15M total) on 2026-06-12.

Original reporting
SEC EDGAR · Penczek Ronald W
Published Jun 15, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not include any operational, financial, or regulatory development for Elevance Health.

02

Market read

Traders may note insider selling, but the disclosure lacks a fundamental catalyst and is unlikely to drive sustained repricing on its own.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional filings or context, signal quality is limited.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-15 (after the 2026-06-12 sale)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

SEC Form 4 shows Elevance Health CAO & Controller Penczek sold 369 shares in an open-market transaction on 2026-06-12.

Expected impact

Low near-term impact; any reaction is likely muted unless part of a larger pattern.

Evidence & confidence

The filing is a Form 4 insider transaction with no stated earnings, guidance, or regulatory catalyst; it also notes no 10b5-1 plan, but the disclosed size is modest (about $149k).

Market effects

Minimal; single-company insider sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “scheduled” selling, but the transaction size is small and not tied to any new company event.

Key entities

  • Elevance Health, Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Ronald W. Penczek

    CAO & Controller who sold 369 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra